Effective at the market close on Monday, April 6, 2020, FTSV will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On March 2, 2020, Forty Seven agreed to be acquired by Gilead for $95.50 per share in cash.
